A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies

Inclusion Criteria: * ≥ 18 years of age at the signing of ICF. * Patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors who cannot be treated surgically and have failed standard of care (SoC). Or patients with refractory/relapsed lymphomas. * MTAP deficiency is confirmed by IHC or NGS. * At least one evaluable tumor lesion at screening for patients in escalation part, and at least one measurable tumor lesion for patients in expansion part. * ECOG performance status of 0 to 1. * Adequate hematopoietic function, cardiac function, liver function, renal function, and coagulation function per local laboratory. Exclusion Criteria: * Female patients in pregnancy or lactation. * Patients with dysphagia; or a condition that seriously affects gastrointestinal absorption. * Allergic or intolerant to the active ingredients or excipients of the investigational product. * Anti-tumor therapy within 28 days of study day 1. * Prior treatment with an methionine adenosyltransferase 2α (MAT2A) inhibitor or a protein arginine methyltransferase 5 (PRMT5) inhibitor. * Central nervous system (CNS) metastasis at screening. * Live vaccine therapy within 4 weeks before study drug administration. * Use of therapeutic anti-coagulation for treatment of active thromboembolic events. * Use of prescription medications that are known strong inducers or inhibitors of cytochrome P450 3A4 (CYP3A4) within 14 days or 5 half-lives (whichever is longer) before study day 1. * Unresolved toxicity from prior anti-cancer therapy. * Active infection of HIV, HBV or HCV. * Patients who are judged by the investigator to have a history of other serious systemic diseases, or not suitable for participating in the trial for any other reason.